Computational Framework Ranks Safer RNA-LNP Formulations Before the Lab

RNA therapeutics have moved from the margins of molecular biology to the center of modern medicine, but the problem that once seemed purely chemical has become a problem of balance. A delivery formulation must ferry RNA into cells efficiently, yet it must avoid triggering the very immune defenses that would neutralize the therapy or, worse, cause harm. Choosing among thousands of possible lipid nanoparticle designs in the laboratory is slow and expensive, and the trade-offs between efficacy and safety are often only discovered after costly experiments. A new study published in BMC Bioinformatics by Valentina Di Salvatore, Giulia Russo, and Francesco Pappalardo of the University of Catania proposes a way to confront that trade-off computationally, before a single formulation is synthesized.

The researchers describe a modular Safety-by-Design framework built around two complementary analytical branches. The first branch is dedicated to candidate prioritization: given a large space of possible RNA-lipid nanoparticle designs, it identifies which formulations best satisfy competing objectives of efficacy and safety. The second branch addresses a subtler question, namely whether the biological picture produced by the framework remains consistent with what is known about human immune organization. By separating these two tasks, the authors argue, the framework avoids the common pitfall of blending mechanistic interpretation, formulation ranking, and biological validation into a single opaque pipeline.

At the heart of the prioritization branch sits a deliberately constructed synthetic design space of 500 RNA-LNP formulations. Each formulation is evaluated across a heterogeneous cohort of virtual patients, computational stand-ins whose simulated immune responses capture variability among real people. From these simulations the framework derives five synthetic endpoints related to efficacy and safety, which are then condensed into a composite Safety-by-Design score. The score is not a single magic number imposed from above; rather, it is a transparent aggregation that can be interrogated, reweighted, and stress-tested, which is precisely what the authors do in a series of sensitivity analyses.

To make the exploration of 100,000 possible patient-formulation pairs tractable, the team trained a Random Forest surrogate model to reproduce the composite score. The model performed well within the synthetic design space: in formulation-grouped five-fold cross-validation, it achieved a pooled out-of-fold coefficient of determination of 0.887, with a root mean square error of 0.055 and a mean absolute error of 0.044. Grouping the cross-validation by formulation is an important methodological choice, because it tests whether the model generalizes to formulations it has not seen, rather than merely memorizing patient-level variation within a familiar formulation.

With the surrogate in place, the researchers turned to Pareto-based multi-objective analysis, a technique borrowed from optimization theory in which a candidate is considered non-dominated if no alternative is better on every objective simultaneously. The primary analysis identified 21 such non-dominated formulations, representing the efficient frontier of the efficacy-safety trade-off. Among these, one candidate, designated LNP_0462, ranked first globally. Crucially, it also ranked first when the analysis was repeated separately within strata of low, intermediate, and high inflammatory risk, suggesting that its leading position is not an artifact of averaging across patient subgroups with very different immune profiles.

Robustness was examined from several angles. The authors tested 3,876 alternative weight combinations for the Safety-by-Design score and found that the ranking was generally stable across them, indicating that the conclusions do not hinge on one particular way of trading efficacy against safety. They also performed a complete balanced analysis of all 100,000 patient-formulation pairs, rather than relying on sampled subsets, and the resulting ranking closely matched the primary analysis, with a Spearman correlation of 0.998 and an overlap of 18 of the top 20 candidates. For a framework intended to guide experimental prioritization, this kind of internal consistency matters as much as raw predictive accuracy.

The second branch of the framework tackles biological plausibility in a way that is deliberately kept apart from the ranking machinery. The authors drew on trajectories generated by the Universal Immune System Simulator, a mechanistic model published in previous work, and condensed descriptors from those trajectories into five Mechanistically Informed Immune Signatures, or MIIS. These signatures were used to constrain synthetic multi-omics profiles, which were then compared at the level of immune programs with an independent human single-cell RNA-sequencing dataset, GSE171964. Importantly, the MIIS variables and the synthetic multi-omics profiles were not used as predictors, endpoint inputs, or Pareto objectives, so the consistency assessment cannot inflate the ranking itself.

The comparison was quantified with a metric the authors call BPCI, computed across seven post-vaccination days. The mean BPCI was 0.760, and it exceeded an exact shuffled-label null with a p-value of 0.025. The authors are careful, however, not to oversell this result. Day-specific evidence was heterogeneous, and donor-level uncertainty was substantial, so the finding supports the general idea that the framework’s synthetic outputs organize immune programs in a manner consistent with real human data, rather than validating any individual formulation’s clinical behavior. The MIIS branch, as the authors put it, provides an assessment of immune-program organization, not a validation of specific candidates.

This restraint is characteristic of the paper’s overall posture. The work is explicitly labeled a proof of concept, and the authors state that experimental testing and evaluation in additional human datasets are required before any conclusions can be drawn about biological or clinical performance. The study involved no new human participants or animals; it relied on computational simulations, synthetic data, and secondary analysis of a publicly available, de-identified transcriptomic dataset, so no additional ethics approval was required. The research received no specific grant funding, and the authors declare no competing interests. The article was received on 28 July 2026, accepted on 27 August 2026, and published open access on 7 September 2026.

Even as a proof of concept, the framework points toward a shift in how RNA therapeutics might be developed. Instead of treating formulation design, safety assessment, and biological plausibility as separate silos handled by different teams at different stages, the Catania group’s approach integrates them into one transparent, modular pipeline in which every assumption can be varied and every ranking can be stress-tested. The surrogate model makes exhaustive exploration affordable, the Pareto analysis makes trade-offs explicit rather than hidden in a weighted average, and the MIIS branch provides an independent sanity check against real human immunology. If subsequent experimental work confirms that computationally prioritized candidates such as LNP_0462 translate into safe and effective formulations, frameworks of this kind could become a standard first filter in the design of RNA-LNP therapeutics, narrowing the laboratory search space and, ultimately, shortening the path from molecular design to clinical candidate.

Subject of Research: A computational Safety-by-Design framework for prioritizing RNA-lipid nanoparticle formulations and assessing biological consistency

Article Title: A modular Safety-by-Design framework for RNA-LNP prioritization and mechanistically informed biological consistency assessment

Article References: Di Salvatore, V., Russo, G., & Pappalardo, F. (2026). A modular Safety-by-Design framework for RNA-LNP prioritization and mechanistically informed biological consistency assessment. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06630-w

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06630-w

Keywords: RNA therapeutics, lipid nanoparticles, Safety-by-Design, virtual patients, Random Forest, Pareto optimization, mechanistic modeling, systems immunology, synthetic multi-omics, single-cell RNA sequencing, explainable artificial intelligence, drug safety